

Comment on the Appraisal Consultation Document for the NICE Single Technology Appraisal

Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs

The Royal College of Pathologists answers to questions posed by the appraisal committee are as follows:

- Has all of the relevant evidence been taken into account? **Yes**
- Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence? **Yes**
- Are the provisional recommendations sound and a suitable basis for guidance to the NHS? **Yes**
- Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexual orientation, religion or belief? **No**
- Are there any equality -related issues that need special consideration and are not covered in the appraisal consultation document? **No**

[Redacted signature]

(Representing the Royal College of Pathologists)